Biological Therapy of Crohn’s Disease in Ukraine

A.E. Dorofeyev, O.A. Rassokhina, A.Yu. Butova

Abstract


The article assesses the state of the problem of Crohn’s disease (CD) in Ukraine and the world. There has been carried out a comparative analysis of the effectiveness of using standard, as well as biological therapy in the treatment of CD by the data of prospective randomized trials. Own data on the effectiveness of biological therapy in 47 patients with inflammatory bowel disease are provided, as well as a clinical case of the use of tumor necrosis factor α antagonists. The use of drugs of biological therapy is highly effective in patients with CD in inefficiency of standard therapy, may prolong the periods of stable clinical and endoscopic remission, delay the onset of complications and the need for surgical interventions that will improve the quality of life of patients with CD.

References


Lichtenstein G.R., Hanauer S.B., Sandborn W.J., the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s Disease in Adults // Am. J. Gastroenterol. — 2009 Feb. — 104 (2). — 465-83.

Bernstein C.N., Fried M., Krabshuis J.H. et al. World Gastroenterology Organisation Global Guidelines. Inflammatory bowel disease: a global perspective. — World Gastroenterology Organization, 2009. — 1-24.

Molodecky N.A., Soon I.S., Rabi D.M. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review // Gastroenterology. — 2012. — 142 (1). — 46-54.

Dignass A., Van Assche G., Lindsay J.O. et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Current management // Journal of Crohn’s and Colitis. — 2010. — 4. — 28-62.

Satsangi J., Silverberg M.S., Vermeire S.,

Colombel J.-F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications // Gut. — 2006. — 55. — 749-753.

Peyrin-Biroulet L., Loftus E.V., Colombel J.F., Sandborn W.J. The Natural History of Adult Crohn’s Disease in Population-Based Cohorts // Am. J. Gastroenterol. — 2010. — 105. — 289-297.

Loftus E.V., Schoenfeld P., Sandborn W.J. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review // Aliment. Pharmacol. Ther. — 2002. — 16. — 51-60.

Van Assche G., Dignass A., Panes J. et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis // Journal of Crohn’s and Colitis. — 2010. — 4. — 7-27.

Hanauer S.B. Inflammatory bowel disease: epidemiology, pathogenesis and therapeutic opportunities // Inflamm. Bowel Dis. — 2006. — 12 (Suppl. l). — S3-9.

Rogler G. The effects of NOD2/CARD15 mutations on the function of the intestinal barrier // Journal of Crohn’s and Colitis. — 2007. — 1 (2). — 53-60.

Abraham C., Cho J. Inflammatory Bowel Disease // N. Engl. J. Med. — 2009. — 361. — 2066-78.

Andrews J.M. Australian Guidelines for General Practitioners and Physicians. Inflammatory Bowel Disease. — 3rd ed. — 2013. — P. 31.

Pariente B., Cosnes J., Danese S. et al. Development of the Crohn’s Disease Digestive Damage Score, the Lemann Score // Inflamm. Bowel Dis. — 2011. — 17(6). — 1414-1422.

Rahier J.F., Ben-Horin S., Chowerset Y. et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease // Journal of Crohn’s and Colitis. — 2009. — 3. — 47-91.

Tracey D., Klareskog L., Sasso E.H. et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review // Pharmacology & Therapeutics. — 2008. — 117. — 244-279.

Hanauer S.B. Positioning Biologic Agents in the Treatment of Crohn’s Disease // Inflamm. Bowel Dis. — 2009. — 15. — 1570-1582.

D’Haens G., Baert F., van Assche G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial // Lancet. — 2008. — 371 (9613). — 660-7.

Karmiris K. et al. Influence of trough serum levels and immunogenicity long-term outcome of adalimumab therapy in Crohn’s disease // Gastroenterol. — 2009. — 137. — 1628-1640.

Sandborn W.J. et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial // Gut. — 2007. — 56. — 1232-1239.

Schreiber S. et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease // Gastroenterol. — 2005. — 129. — 807-818.

Colombel J.F., Sandborn W.J., Reinisch W. et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease // N. Engl. J. Med. — 2010. — 362 (15). — 1383-95.

Hanauer S.B., Sandborn W.J., Rutgeerts P. et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC I trial // Gastroenterology. — 2006. — 130. — 323-333.

Schreiber S., Reinisch W., Colombel J.F. et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease // Journal of Crohn’s and Colitis. — 2013. — 7. — 213-221.

Rutgeerts P., Van Assche G., Sandborn W.J., Wolf D.C. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial // Gastroenterology. — 2012. — 142. — 1102-1111.

Jones J.L., Kaplan G.G., Peyrin-Biroulet L. et al. // Gastroenterology. — 2013. — 144 (Suppl. 1). — S179.

Sandborn W.J., Rutgeerts P., Enns R. et al. Adalimumab induction therapy for Crohns disease previously treated with infliximab // Ann. Intern. Med. — 2007. — 146 (12). — 829-838.

Hoentjen F., Haarhuis B., Drenth J. et al. Elective Switching from Infliximab to Adalimumab in Stable Crohn’s Disease // Inflamm. Bowel Dis. — 2013. — 19. —

-766.

Vavricka S.R., Bentele N., Scharl M. et al. Systematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an antitumor necrosis factor agent (CHOOSE TNF TRIAL) // Inflamm. Bowel Dis. — 2012. — 18. — 1523-1530.




DOI: https://doi.org/10.22141/2308-2097.1 (51).2014.81913

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru